Cargando…
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the available therapeutic options show a lack of efficacy, novel therapeutic strategies are urgently needed. Given its T-cell infiltration, we hypothesized that MPM is a suitable target for therapeutic cancer vacci...
Autores principales: | Chiaro, Jacopo, Antignani, Gabriella, Feola, Sara, Feodoroff, Michaela, Martins, Beatriz, Cojoc, Hanne, Russo, Salvatore, Fusciello, Manlio, Hamdan, Firas, Ferrari, Valentina, Ciampi, Daniele, Ilonen, Ilkka, Räsänen, Jari, Mäyränpää, Mikko, Partanen, Jukka, Koskela, Satu, Honkanen, Jarno, Halonen, Jussi, Kuryk, Lukasz, Rescigno, Maria, Grönholm, Mikaela, Branca, Rui M., Lehtiö, Janne, Cerullo, Vincenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624665/ https://www.ncbi.nlm.nih.gov/pubmed/37923723 http://dx.doi.org/10.1038/s41467-023-42668-7 |
Ejemplares similares
-
A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines
por: Feola, Sara, et al.
Publicado: (2022) -
GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
por: Hamdan, Firas, et al.
Publicado: (2021) -
Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses
por: Hamdan, Firas, et al.
Publicado: (2023) -
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine
por: Feola, Sara, et al.
Publicado: (2022) -
PeptiCHIP:
A Microfluidic Platform for Tumor Antigen
Landscape Identification
por: Feola, Sara, et al.
Publicado: (2021)